علاج سرطان الدم النقوي المزمن في المرحلة المتسارعة

References

DOI: 10.1002/ajh.27443

• CML can be classified into three phases: CP, accelerated phase (AP), and blast phase (BP).
• Patients with CML-AP or CML-BP may receive initial therapy with TKIs (newer generation TKIs like dasatinib or ponatinib preferred over imatinib) to reduce the CML burden and be considered for early allo-HSCT.
• Patients with de novo CML-AP are treated with frontline second-generation TKI indefinitely if an optimal response (CCyR; BCR::ABL1 transcripts [IS] <1%) is achieved within 6 months of therapy.